CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation

Circulation Research

Volumn 92, Issue 9, 2003, Pages 1041-1048

  Inwald, David P ^a   McDowall, Alison ^b   Peters, Mark J ^a   Callard, Robin E ^a   Klein, Nigel J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Atherosclerosis; CD40 CD40L; Inflammation; Platelets; Thrombosis

Indexed keywords

BETA3 INTEGRIN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; EPTIFIBATIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M2; MONOCLONAL ANTIBODY M3; PADGEM PROTEIN; PROTEIN TRAP 1; RECOMBINANT ANTIGEN; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL GRANULE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; LEUKOCYTE ADHERENCE; LIGAND BINDING; MEGAKARYOCYTE; NEUTROPHIL CHEMOTAXIS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLUBILITY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANTIGENS, CD40; BLOOD PLATELETS; CALCIUM; CD40 LIGAND; CELL ADHESION; CELL LINE; CELL SIZE; HUMANS; INTEGRIN BETA3; ION TRANSPORT; NEUTROPHILS; P-SELECTIN; PLATELET ACTIVATION; SECRETORY VESICLES;

EID: 0037877918     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000070111.98158.6C     Document Type: Article

References (45)

1. Paulie S, Ehlin-Henriksson B, Mellstedt H, Kobo H, Ben Aissa H, Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother. 1985;20: 23-28.
2. Korthauer U. Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361:539-541.
3. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A. 1995; 92:4342-4346.
4. Dechanet J, Grosset C, Taupin JL, Merville P, Banchereau J, Ripoche, Moreau JF. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol. 1997;159:5640-5647.
5. Kotowicz K, Dixon GL, Klein NJ, Peters MJ, Callard RE. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology. 2000;100:441-448.
6. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178:669-674.
7. Kiener PA, Moran DP, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. 1995;155:4917-4925.
8. Mach F, Schonbeck U, Bonnefoy JY. Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
9. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
10. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203.
11. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
12. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
13. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008-1014.
14. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L. the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896-899.
15. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation. 1999;100:614-620.
16. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, Klinghammer L, Daniel WG, Schmeisser A. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001;86:649-655.
17. Nannizzi-Alaimo L, Rubenstein MH, Alves VL. Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002;105:2849-2854.
18. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory reaction of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98: 1047-1054.
19. Fanslow WC, Rousseau AC, Lofton TE, Klinke R, Ulrich DT, Armitage RJ. CD154 (CD40 ligand) workshop panel report. In: Kishimoto T. ed. Leucocyte Typing VI. New York, NY: Garland Publishing, Inc; 1997: 101-103.
20. Fanslow WC, Clifford KN, Zappoen J, Alderson MR, Armitage RJ. CD40 mAb M2 and M3 inhibit CD40 ligand binding and function. In: Schlossman SF, Boumsell L, Gilks W, eds. Leukocyte Typing V. Oxford, UK: Oxford University Press; 1995:555-556.
21. Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CB. Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. J Immunol. 1996; 157:1652-1658.
22. Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. Br J Haematol. 1990;76:387-394.
23. McDowall A, Inwald D, Leitinger B, Jones A, Liesner R, Klein N, Hogg N. A novel form of integrin dysfunction involving β1, β2, and β3 integrins. J Clin Invest. 2003;111:51-60.
24. 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
25. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, Klein NJ. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol. 1999;106:391-399.
26. Inwald DP, Peters MJ, Walshe D, Jones A, Davies G, Klein NJ. Absence of platelet CD40L identifies patients with X linked hyper IgM syndrome. Clin Exp Immunol. 2000;120:499-502.
27. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990;75:550-554.
28. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997;100:S97-S103.
29. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIbIIIa complex during platelet activation. J Biol Chem. 1985;260:11107-11114.
30. Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, Ganz P, Briscoe DM. CD40 and CD40 ligand are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation. 1997;64: 1765-1774.
31. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages. Proc Natl Acad Sci U S A. 1997;94:1931-1936.
32. Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol. 2000;111:474-481.
33. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395-2400.
34. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999;104:947-955.
35. Viallard JF, Solanilla A, Gauthier B, Contin C, Dechanet J, Grosset C, Moreau JF, Praloran V, Nurden P, Pellegrin JL, Nurden AT, Ripoche J. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99: 2612-2614.
36. Morris AE, Remmele RL Jr, Klinke R, Macduff BM, Fanslow WC, Armitage RJ. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem. 1999;274: 418-423.
37. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 1996;271:5965-5967.
38. Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 1993;5:233-238.
39. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, Thomas D. A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3:1031-1039.
40. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645-2657.
41. Park SM, Kim HS, Choe J, Lee TH. Differential induction of cytokine genes and activation of mitogen-activated protein kinase family by soluble CD40 ligand and TNF in a human follicular dendritic cell line. J Immunol. 1999;163:631-638.
42. Rink TJ, Sanchez A, Hallam TJ. Diacylglycerol and phorbol ester stimulate secretion without raising cytoplasmic free calcium in human platelets. Nature. 1983;305:317-319.
43. Watson SP, Hambleton S. Phosphorylation-dependent and -independent pathways of platelet aggregation. Biochem J. 1989;258:479-485.
44. Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb Haemost. 1996;76: 780-785.
45. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA. 2000;97: 6930-6932.